AzTrials
AzTrials

Attention Deficit Hyperactivity DisorderNCT00143832

Genetic Risk for Attention Deficit Hyperactivity Disorder Expressed in Brain Functioning

An observational study of Attention Deficit Hyperactivity Disorder, run by UMC Utrecht at 1 site in Netherlands.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Poor inhibitory control has been proposed to be central to the cognitive deficits and symptomatology associated with Attention Deficit Hyperactivity Disorder (ADHD). ADHD is a highly heritable disorder with an increased incidence among the siblings of affected individuals. Read more about this study

Who is it for?
Ages 8 to 20 years, men onlyHealthy volunteers can take part
Conditions the study is for
Attention Deficit Hyperactivity Disorder
How many people
90 participants
Where
1 siteNetherlands
Study dates
Sep 2004to not given
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 8 to 20 years
  • Men only
  • Healthy volunteers accepted
  • Child, Adult

Who may be able to join

  • Age 8 - 20 years
  • Male
  • DSM-IV (APA, 1994) diagnosis of ADHD, according to DISC interview
  • Scores in the clinical range on the Child Behavior Checklist (CBCL) and Teacher Rating Form(TRF)
  • One brother who meets the inclusion criteria for siblings
  • No DSM-IV (APA, 1994) diagnosis according to DISC interview
Show all 9Show fewer
  • No scores in the clinical range on the Child Behavior Checklist (CBCL) and Teacher Rating Form (TRF)
  • No DSM-IV (APA, 1994) diagnosis, according to DISC interview
  • No scores in the clinical range on the Child Behavior Checklist (CBCL) and Teacher Rating Form (TRF)

Who cannot join

  • IQ < 70
  • Illness of the cardiovascular, the endocrine, the pulmonal or the gastrointestinal system
  • Presence of metal objects in or around the body (pacemaker, dental braces)
  • History of or present neurological disorder
  • For individuals over 12 years of age: legal incompetence, defined as the obvious inability to comprehend the information that is presented by the investigator and is outlined in the Information letter and on which the decision to participate in the study is to be based

Trial locations and contacts

1 site in 1 country.

Sarah Durston, Ph.D. contact

+31 30 250 8161

S.Durston@umcutrecht.nl

Netherlands1 site, 1 recruiting
  • Dept. of Child and Adolescent Psychiatry, UMC Utrecht

    Utrecht

    Martijn Mulder, M.Sc., +31 30 250 8161, M.Mulder-7@azu.nl

    Janna van Belle, M.Sc., +31 30 250 3275, J.vanBelle@umcutrecht.nl

    Recruiting

Other trials in Netherlands

About this study

Poor inhibitory control has been proposed to be central to the cognitive deficits and symptomatology associated with Attention Deficit Hyperactivity Disorder (ADHD). ADHD is a highly heritable disorder with an increased incidence among the siblings of affected individuals. In the current proposal we investigate the expression of genetic susceptibility for ADHD in brain functioning. We will study cognitive functioning in patients with ADHD, their unaffected siblings and healthy matched controls. Our aims are 1) to determine whether increased familial risk for ADHD is associated with differential patterns of brain activation compared to normally developing children, during the performance of tasks designed to probe cognitive functions that are compromised in ADHD and 2) to determine whether differential patterns of activation are similar for boys with ADHD and their unaffected siblings.

Read the detailed description

Poor inhibitory control has been proposed to be central to the cognitive deficits and symptomatology associated with Attention Deficit Hyperactivity Disorder (ADHD). ADHD is a highly heritable disorder with an increased incidence among the siblings of affected individuals. Although studies investigating candidate genes are underway, as yet it remains unclear via which mechanisms the presence of risk genes leads to symptomatology. There is evidence to suggest that individuals at increased genetic risk display some of the cognitive deficits associated with the disorder. In particular poor inhibitory control has been put forward as a potential marker for familial ADHD. Neuroimaging techniques now make it possible to investigate the neural substrate of cognitive deficits associated with psychiatric disorders. Magnetic resonance imaging (MRI) has been used to demonstrate that the neural substrate of cognitive brain function is affected in ADHD. Using a task that taxes inhibitory systems at varying levels of task demands, we demonstrated that increased susceptibility to interference in children with ADHD is paralleled by differences in brain activation, with these children displaying a relative lack of fronto-striatal activation. In a recent study, we demonstrated that the unaffected siblings of patients with ADHD show cortical volumetric deficits, similar to patients themselves. This suggests that individuals at increased risk for ADHD share some of the neural basis of cognitive deficits associated with this disorder. In the current proposal we set out to investigate the expression of genetic susceptibility for ADHD in brain functioning. We will study cognitive functioning in patients with ADHD, their unaffected siblings and healthy matched controls focusing on cognitive control. Our aims are 1) to determine whether increased familial risk for ADHD is associated with differential patterns of brain activation compared to normally developing children, during the performance of tasks designed to probe cognitive functions that are compromised in ADHD and 2) to determine whether differential patterns of activation are similar for boys with ADHD and their unaffected siblings. We intend to include 30 boys with ADHD, 30 of their brothers without ADHD, and 30 matched normal controls in 3 studies focusing on cognitive control and similar cognitive functions that are compromised in ADHD. We will include 10 boys in each group for each study. The proposed studies will utilize variations of a parametric go nogo paradigm previously developed. All subjects will be asked to participate in a functional MR scanning session lasting up to an hour. The whole visit will last a maximum of two hours. There are no known risks associated with MR scanning, therefore this procedure is considered completely safe. By participating in a simulation prior to the scan, we will also minimize anxiety for the subjects. Furthermore, the study will immediately be terminated if a subject becomes anxious, or otherwise indicates that he no longer wishes to participate. All subjects will be offered a gift certificate as a token of appreciation for their effort. In addition, they will be reimbursed for travel expenses.

Keywords
fMRI
Medical subject headings
Attention Deficit Disorder with Hyperactivity

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Sep 2005 (estimated)
  2. Study startSep 2004

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Other
Enrolment
90 participants
IDs, dates and publications
ClinicalTrials.gov ID
NCT00143832
Sponsor's protocol ID
P03.0465C
Other IDs
METC 04/124
Status last verified
Mar 2007
First submitted
31 Aug 2005
Last updated
20 Mar 2007
Results posted
No

Publications

  • Durston S, Mulder M, Casey BJ, Ziermans T, van Engeland H. Activation in ventral prefrontal cortex is sensitive to genetic vulnerability for attention-deficit hyperactivity disorder. Biol Psychiatry. 2006 Nov 15;60(10):1062-70. doi: 10.1016/j.biopsych.2005.12.020. Epub 2006 May 19.

    PubMed 16712804
  • Durston S, Fossella JA, Mulder MJ, Casey BJ, Ziermans TB, Vessaz MN, VAN Engeland H. Dopamine transporter genotype conveys familial risk of attention-deficit/hyperactivity disorder through striatal activation. J Am Acad Child Adolesc Psychiatry. 2008 Jan;47(1):61-67. doi: 10.1097/chi.0b013e31815a5f17.

    PubMed 18174826

Questions about this trial

What is this clinical trial studying?

An observational study of Attention Deficit Hyperactivity Disorder, run by UMC Utrecht at 1 site in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 20 Mar 2007. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Sarah Durston, Ph.D. (+31 30 250 8161, S.Durston@umcutrecht.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00143832, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Mar 2007.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in